[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254
|
[2]
|
Fall, B., Tengue, K., Sow, Y., Sarr, A., Thiam, A., Mohamed, S., et al. (2012) Place de la pulpectomie bilatérale dans la suppression androgénique pour cancer de la prostate. Progrès en Urologie, 22, 344-349. https://doi.org/10.1016/j.purol.2011.12.005
|
[3]
|
Gueye, S.M., Jalloh, M., Labou, I., Niang, L., Kane, R. and Ndoye, M. (2004) Profil clinique du cancer de la prostate au Sénégal. African Journal of Urology, 10, 203-207.
|
[4]
|
Huggins, C. and Hodges, C.V. (1972) Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. CA: A Cancer Journal for Clinicians, 22, 232-240. https://doi.org/10.3322/canjclin.22.4.232
|
[5]
|
Khoury, S. (2012) Cancer de la prostate Hormono-indépendant. Progrès en Urologie, 1202, 7-18.
|
[6]
|
Crawford, E.D., Petrylak, D. and Sartor, O. (2017) Navigating the Evolving Therapeutic Landscape in Advanced Prostate Cancer. Urologic Oncology, 35, 1-13. https://doi.org/10.1016/j.urolonc.2017.01.020
|
[7]
|
Rozet, F., Hennequin, C., Beauval, J.-B., Beuzeboc, P., Cormier, L., Fromont, G., et al. (2016) Recommandations en onco-urologie 2016-2018 du CCAFU: Cancer de la prostate. Progrès en Urologie, 27, 95-144. https://doi.org/10.1016/S1166-7087(16)30705-9
|
[8]
|
Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, M., Thiam, I., et al. (2013) Cancer de la prostate: Quelle prise en charge au Sénégal? Progrès en Urologie, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002
|
[9]
|
Higano, C.S. and Crawford, E.D. (2011) New and Emerging Agents for the Treatment of Castration-Resistant Prostate Cancer. Urologic Oncology, 29, 1-8. https://doi.org/10.1016/j.urolonc.2011.08.013
|
[10]
|
Wade, C. and Kyprianou, N. (2018) Profiling Prostate Cancer Therapeutic Resistance. International Journal of Molecular Sciences, 19, 904. https://doi.org/10.3390/ijms19030904
|
[11]
|
Rigaud, J., Le Normand, L., Karam, G., Glémain, P., Buzelin, J.-M. and Bouchot, O. (2002) Facteurs pronostiques du cancer de la prostate traité par hormonothérapie de première intention. Progrès en Urologie, 12, 232.
|
[12]
|
Mulders, P.F., Dijkman, G.A., Fernandez del Moral, P., Theeuwes, A.G. and Debruyne, F.M. (1990) Analysis of Prognostic Factors in Disseminated Prostatic Cancer. An Update. Dutch Southeastern Urological Cooperative Group. Cancer, 65, 2758-2761. https://doi.org/10.1002/1097-0142(19900615)65:12<2758::AID-CNCR2820651225>3.0.CO;2- 6
|
[13]
|
Emrich, L.J., Priore, R.L., Murphy, G.P. and Brady, M.F. (1985) Prognostic Factors in Patients with Advanced Stage Prostate Cancer. Cancer Research, 45, 5173-5179.
|
[14]
|
Angwafo, F.F. (1998) 3rd. Re: Prostate Cancer in Nigerians: Facts and Nonfacts. Journal of Urology, 160, 135. https://doi.org/10.1016/S0022-5347(01)63068-4
|
[15]
|
Chodak, G.W., Vogelzang, N.J., Caplan, R.J., Soloway, M. and Smith, J.A. (1991) Independent Prognostic Factors in Patients with Metastatic (Stage D2) Prostate Cancer. The Zoladex Study Group. JAMA, 265, 618-621. https://doi.org/10.1001/jama.1991.03460050072023
|
[16]
|
Oosterlinck, W., Mattelaer, J., Casselman, J., Van Velthoven, R., Derde, M.P. and Kaufman, L. (1997) PSA Evolution: A Prognostic Factor during Treatment of Advanced Prostatic Carcinoma with Total Androgen Blockade. Data from a Belgian Multicentric Study of 546 Patients. Acta Urologica Belgica, 65, 63-71.
|
[17]
|
Oosterlinck, W., Mattelaer, J., Derde, M.P. and Kaufman, L. (1995) Prognostic Factors in Advanced Prostatic Carcinoma Treated with Total Androgen Blockade. Flutamide with Orchiectomy or with LHRH Analogues. A Belgian Multicentric Study of 546 Patients. Acta Urologica Belgica, 63, 1-9.
|
[18]
|
Jørgensen, T., Kanagasingam, Y., Kaalhus, O., Tveter, K.J., Bryne, M., Skjørten, F., et al. (1997) Prognostic Factors in Patients with Metastatic (Stage D2) Prostate Cancer: Experience from the Scandinavian Prostatic Cancer Group Study-2. Journal of Urology, 158, 164-170. https://doi.org/10.1097/00005392-199707000-00052
|
[19]
|
Robinson, D. (2008) Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline Phosphatase. Journal of Urology, 179, 117-123. https://doi.org/10.1016/j.juro.2007.08.132
|
[20]
|
Johansson, J.E., Andersson, S.O., Holmberg, L. and Bergström, R. (1991) Prognostic Factors in Progression-Free Survival and Corrected Survival in Patients with Advanced Prostatic Cancer: Results from a Randomized Study Comprising 150 Patients Treated with Orchiectomy or Estrogens. Journal of Urology, 146, 1327-1333. https://doi.org/10.1016/S0022-5347(17)38081-3
|
[21]
|
Sine, B., Bagayogo, N.A., Thiam, A., Sarr, A., Zakou, A.R., Faye, S.T., et al. (2016) Cancers de la prostate de score de Gleason supérieur ou égal à 8: Evaluation de la survie des patients. African Journal of Urology, 22, 243-248. https://doi.org/10.1016/j.afju.2016.01.011
|
[22]
|
Gagnat, A., Larré, S., Fromont, G., Pirès, C., Doré, B. and Irani, J. (2011) La survie est associée au délai d’atteinte du PSA nadir (DAN) et au ratio DAN/valeur nadir après suppression androgénique pour cancer de prostate. Progrès en Urologie, 21, 341-348. https://doi.org/10.1016/j.purol.2010.09.024
|
[23]
|
Halabi, S., Kelly, W.K., Ma, H., Zhou, H., Solomon, N.C., Fizazi, K., et al. (2016) Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 34, 1652-1659. https://doi.org/10.1200/JCO.2015.65.7270
|
[24]
|
Choueiri, T.K., Xie, W., D’Amico, A.V., Ross, R.W., Hu, J.C., Pomerantz, M., et al. (2009) Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen-Deprivation Therapy. Cancer, 115, 981-987. https://doi.org/10.1002/cncr.24064
|
[25]
|
Nayyar, R., Sharma, N. and Gupta, N.P. (2010) Prognostic Factors Affecting Progression and Survival in Metastatic Prostate Cancer. Urologia Internationalis, 84, 159-163. https://doi.org/10.1159/000277592
|
[26]
|
Hori, S., Jabbar, T., Kachroo, N., Vasconcelos, J.C., Robson, C.N. and Gnanapragasam, V.J. (2011) Outcomes and Predictive Factors for Biochemical Relapse Following Primary Androgen Deprivation Therapy in Men with Bone Scan Negative Prostate Cancer. Journal of Cancer Research and Clinical Oncology, 137, 235-241. https://doi.org/10.1007/s00432-010-0877-9
|